Study | Phase | Treatment status | HER-2 therapy | Pts no. | Dosage | Chemotherapy | Efficacy endpoint | Patients status |
---|---|---|---|---|---|---|---|---|
Luca Gianni 2018 [22] | 2 | Neoadjuvant | P + T | 30 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Palbociclib, Fulvestrant | pCR safety | Unilateral invasive, HER2-positivebreast cancer |
Julia Foldi 2017 [23] | 2 | Neoadjuvant | P + T | 48 | During weeks 1–12, 840 mg → 420 mg q3w + 4 mg/kg → 2 mg/Kg weekly; During weeks 13–24, 420 mg + 6 mg/kg q3w; | Paclitaxel, FEC | pCR safety | stage I–III, HER2-positive invasive breast cancer |
JASMEET C. SINGH 2017 [24] | retrospective study | Neoadjuvant | P + T | 57 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | AC, Paclitaxel | pCR | operable breast cancer (53) locally advanced disease(3) inflammatory breast cancer(1) |
Shruti R. Tiwari 2016 [25] | retrospective study | Neoadjuvant | P + T | 70 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Docetaxel, Carboplatin | pCR safety | I(6), II(48), and III(16), HER2-positive breast cancer |
MICHAEL ANDERSSON 2017 [26] | 2 | Metastatic | P + T | 107 | co-infusion of 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Vinorelbine | PFS safety | HER2-positive MBC/LABC |
Edith A. Perez 2016 [27] | 2 | Metastatic | P + T | 106 | Infusion of 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w, respectively | Vinorelbine | PFS safety | HER2-positive MBC/LABC |
Chau Dang 2015 [28] | 2 | Metastatic | P + T | 69 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Docetaxel | PFS safety | HER2-positive MBC |
Bao D Dao 2015 [29] | retrospective study | Metastatic | P + T | 19 | NK | Taxane | PFS | HER2-positive MBC |
Kazuhiro Araki 2017 [14] | 2 | Metastatic | P + T | 30 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Eribulin | PFS safety | HER2-positive ABC |
Jose´ Baselga 2010 [30] | 2 | Metastatic | P + T | 66 | 840 mg → 420 mg q3w + 4 mg/kg → 2 mg/kg weekly or 8 mg/kg → 6 mg/kg q3w | NO | PFS safety | HER2-positive MBC |
Chia C. Portera 2008 [31] | 1 | Metastatic | P + T | 11 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | NO | safety | HER2-positive MBC |
Nicholas J. Robert 2017 [32] | retrospective study | Metastatic | P + T | 266 | NK | Taxane | PFS safety | HER2-positive MBC |
Sabino De Placido 2018 [33] | retrospective study | Metastatic | P + T | 155 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Taxane | PFS safety | HER2-positive MBC |
Kathy D. Miller 2014 [34] | Ib/IIa | Metastatic | P + T-DM1 | 64 | 840 mg → 420 mg q3w + 3.6 mg/kg q3w | NO | PFS safety | HER2-positive MBC/LABC |
Peter Beitsch 2017 [10] | prospective | Neoadjuvant | A:P + T B:T | 119 178 | NK | Docetaxel, Carboplatin | pCR | T4 or inflammatory HER2-positive breast cancer |
Luca Giannia 2012 [15] | 2 | Neoadjuvant | A:P + T B:T | 107 107 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w 8 mg/kg → 6 mg/kg q3w | Docetaxel | pCR safety | locally advanced, inflammatory, or early-stage HER2-positive breast cancer |
Gunter von Minckwitz 2017 [16] | prospective | Adjuvant | A:P + T B:T | 2400 2405 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w 8 mg/kg → 6 mg/kg q3w | FEC, Docetaxel or Paclitaxel, Carboplatin | safety | HER2-Positive EBC |
Rashmi K. Murthy 2018 [17] | retrospective study | Neoadjuvant | A:P + T B:T | 170 807 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w 8 mg/kg → 6 mg/kg q3w or 4 mg/kg → 2 mg/kg weekly | Paclitaxel | pCR | Stage II-III,HER-2-positive Breast Cancer |
M. Martin 2016 [13] | I b /IIa | Metastatic | A:P + T-DM1 B:T-DM1 | 33 40 | 840 mg → 420 mg q3w + 3.6 mg/kg q3w 3.6 mg/kg q3w | Docetaxel | pCR safety | HER2-positive MBC/LABC |
Mothaffar Rimawi 2017 [18] | 2 | Metastatic | A:P + T B:T | 129 129 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w 8 mg/kg → 6 mg/kg q3w | AI | PFS safety | HER2-positive MBC/LABC |
Ander Urruticoecheaa 2017 [9] | 3 | Metastatic | A:P + T B:T | 228 224 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w 8 mg/kg → 6 mg/kg q3w | Carboplatin | PFS safety | HER2-positive MBC |
Sandra M. Swaina 2015 [19] | 3 | Metastatic | A:P + T B:T | 402 406 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w 8 mg/kg → 6 mg/kg q3w | Docetaxel | PFS safety | HER2-positive MBC |
Ian E. Kropa 2016 [20] | I b /IIa | Metastatic | A:P + T-DM1 B:T-DM1 | 22 22 | 840 mg → 420 mg q3w + 3.6 mg/kg q3w or 2.4 mg/kg weekly 3.6 mg/kg q3w or 2.4 mg/kg weekly | Paclitaxel | PFS safety | HER2-positive MBC/LABC |
Edith A. Pereza 2017 [21] | 3 | Metastatic | A:P + T-DM1 B:T-DM1 | 363 367 | 840 mg → 420 mg q3w + 3.6 mg/kg q3w 3.6 mg/kg q3w | NO | PFS safety | HER2-positive MBC/LABC |
Manish Gupta 2013 [11] | 2 | Metastatic | A:P + T-DM1 B:T-DM1 | 20 51 | 840 mg → 420 mg q3w + 3.6 mg/kg q3w 3.6 mg/kg q3w | NO | PFS safety | HER2-positive MBC/LABC |
Nadia Hussain 2018 [35] | retrospective study | Neoadjuvant | A:P + T B:T | 22 23 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w 8 mg/kg → 6 mg/kg q3w | Docetaxel, Carboplatin | safety | stages 1–3 HER2-positive breast cancer |